These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

374 related articles for article (PubMed ID: 37376587)

  • 61. Testing the efficacy and safety of BIO101, for the prevention of respiratory deterioration, in patients with COVID-19 pneumonia (COVA study): a structured summary of a study protocol for a randomised controlled trial.
    Dioh W; Chabane M; Tourette C; Azbekyan A; Morelot-Panzini C; Hajjar LA; Lins M; Nair GB; Whitehouse T; Mariani J; Latil M; Camelo S; Lafont R; Dilda PJ; Veillet S; Agus S
    Trials; 2021 Jan; 22(1):42. PubMed ID: 33430924
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Histological and serological features of acute liver injury after SARS-CoV-2 vaccination.
    Codoni G; Kirchner T; Engel B; Villamil AM; Efe C; Stättermayer AF; Weltzsch JP; Sebode M; Bernsmeier C; Lleo A; Gevers TJ; Kupčinskas L; Castiella A; Pinazo J; De Martin E; Bobis I; Sandahl TD; Pedica F; Invernizzi F; Del Poggio P; Bruns T; Kolev M; Semmo N; Bessone F; Giguet B; Poggi G; Ueno M; Jang H; Elpek GÖ; Soylu NK; Cerny A; Wedemeyer H; Vergani D; Mieli-Vergani G; Lucena MI; Andrade RJ; Zen Y; Taubert R; Terziroli Beretta-Piccoli B
    JHEP Rep; 2023 Jan; 5(1):100605. PubMed ID: 36440259
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Liver injury associated with high value of D-dimer plasmatic level in COVID-19 patients.
    Abenavoli L; Aquila I; Sacco MA; Procopio AC; Cinaglia P; Zanza C; Longhitano Y; Arena V; Fagoonee S; Ricci P; Luzza F
    Minerva Gastroenterol (Torino); 2023 Mar; 69(1):141-148. PubMed ID: 35470356
    [TBL] [Abstract][Full Text] [Related]  

  • 64. SARS-CoV-2 induced hepatic injuries and liver complications.
    Saeed U; Piracha ZZ; Uppal SR; Waheed Y; Uppal R
    Front Cell Infect Microbiol; 2022; 12():726263. PubMed ID: 36189356
    [TBL] [Abstract][Full Text] [Related]  

  • 65. SARS-CoV-2 infection in patients with a normal or abnormal liver.
    Cabibbo G; Rizzo GEM; Stornello C; Craxì A
    J Viral Hepat; 2021 Jan; 28(1):4-11. PubMed ID: 33190321
    [TBL] [Abstract][Full Text] [Related]  

  • 66. COVID-19, Mast Cells, Cytokine Storm, Psychological Stress, and Neuroinflammation.
    Kempuraj D; Selvakumar GP; Ahmed ME; Raikwar SP; Thangavel R; Khan A; Zaheer SA; Iyer SS; Burton C; James D; Zaheer A
    Neuroscientist; 2020; 26(5-6):402-414. PubMed ID: 32684080
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Autoimmunity and COVID-19 - The microbiotal connection.
    Katz-Agranov N; Zandman-Goddard G
    Autoimmun Rev; 2021 Aug; 20(8):102865. PubMed ID: 34118455
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Molecular mechanisms implicated in SARS-CoV-2 liver tropism.
    Quarleri J; Delpino MV
    World J Gastroenterol; 2022 Dec; 28(48):6875-6887. PubMed ID: 36632318
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Liver Injury in COVID-19: A Direct Hit or Collateral Damage?
    Vairappan B; Wright G; Corrigal D; Ts R
    Infect Disord Drug Targets; 2022; 22(1):e130921196417. PubMed ID: 34517808
    [TBL] [Abstract][Full Text] [Related]  

  • 70. A brief review of liver injury in patients with Corona Virus Disease-19 during the pandemic.
    Farshidpour M; Kim D; Junna S; Merchant J
    Indian J Gastroenterol; 2020 Jun; 39(3):232-235. PubMed ID: 32621206
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Therapeutic Potential of P2X7 Purinergic Receptor Modulation in the Main Organs Affected by the COVID-19 Cytokine Storm.
    Batista Simões JL; Sobierai LD; Pereira SM; Rodrigues Dos Santos MV; Bagatini MD
    Curr Pharm Des; 2022; 28(22):1798-1814. PubMed ID: 35838210
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Pathological diagnosis of Coronavirus-related nephropathy: insight from postmortem studies.
    Sanguedolce F; Zanelli M; Froio E; Bisagni A; Zizzo M; Ascani S; Stallone G; Netti S; Ranieri E; Falagario U; Carrieri G; Cormio L
    Crit Rev Clin Lab Sci; 2021 Dec; 58(8):563-575. PubMed ID: 34236278
    [TBL] [Abstract][Full Text] [Related]  

  • 73. SARS-CoV-2 multifaceted interaction with human host. Part I: What we have learnt and done so far, and the still unknown realities.
    Delcuve GP; Lakowski TM; Su RC; Beacon TH; Davie JR
    IUBMB Life; 2020 Nov; 72(11):2313-2330. PubMed ID: 32918855
    [TBL] [Abstract][Full Text] [Related]  

  • 74. COVID-19 and Renal Diseases: An Update.
    Bitencourt L; Pedrosa AL; de Brito SBCS; Fróes ACF; de Carvalho ST; Fonseca GG; Ferreira GC; Fradico PF; Simões E Silva AC
    Curr Drug Targets; 2021; 22(1):52-67. PubMed ID: 33050860
    [TBL] [Abstract][Full Text] [Related]  

  • 75. COVID-19 and the liver: A 2021 update.
    Spearman CW; Aghemo A; Valenti L; Sonderup MW
    Liver Int; 2021 Sep; 41(9):1988-1998. PubMed ID: 34152690
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Dysregulated Interferon Response and Immune Hyperactivation in Severe COVID-19: Targeting STATs as a Novel Therapeutic Strategy.
    Eskandarian Boroujeni M; Sekrecka A; Antonczyk A; Hassani S; Sekrecki M; Nowicka H; Lopacinska N; Olya A; Kluzek K; Wesoly J; Bluyssen HAR
    Front Immunol; 2022; 13():888897. PubMed ID: 35663932
    [TBL] [Abstract][Full Text] [Related]  

  • 77. WGO Guidance for the Care of Patients With COVID-19 and Liver Disease.
    Hamid S; Alvares da Silva MR; Burak KW; Chen T; Drenth JPH; Esmat G; Gaspar R; LaBrecque D; Lee A; Macedo G; McMahon B; Ning Q; Reau N; Sonderup M; van Leeuwen DJ; Armstrong D; Yurdaydin C
    J Clin Gastroenterol; 2021 Jan; 55(1):1-11. PubMed ID: 33230011
    [TBL] [Abstract][Full Text] [Related]  

  • 78. SARS-CoV-2-induced liver injury: A review article on the high-risk populations, manifestations, mechanisms, pathological changes, management, and outcomes.
    Payus AO; Mohd Noh M; Azizan N; Muthukaruppan Chettiar R
    World J Gastroenterol; 2022 Oct; 28(39):5723-5730. PubMed ID: 36338886
    [TBL] [Abstract][Full Text] [Related]  

  • 79. SARS-CoV-2 viral liver aggregates and scarce parenchymal infection implicate systemic disease as a driver of abnormal liver function.
    Pepe-Mooney BJ; Smith CJ; Sherman MS; North TE; Padera RF; Goessling W
    Hepatol Commun; 2023 Nov; 7(11):. PubMed ID: 37889528
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Liver injury, SARS-COV-2 infection and COVID-19: What physicians should really know?
    Licata A; Minissale MG; Distefano M; Montalto G
    GastroHep; 2021 May; 3(3):121-130. PubMed ID: 34149320
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.